Overview

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare disease response of Albumin-bound paclitaxel (ABI-007) plus Carboplatin versus Taxol and Carboplatin as first-line therapy in patients with advanced non-small cell lung cancer (NSCLC).
Phase:
Phase 3
Details
Lead Sponsor:
Celgene
Celgene Corporation
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Paclitaxel